Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer (NCT07468903) | Clinical Trial Compass
RecruitingNot Applicable
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
United States45 participantsStarted 2026-05-11
Plain-language summary
This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer. Prostate cancer is the most diagnosed cancer in men and there are many treatments available, including surgery and radiation therapy. Although surgery and radiation therapy improve survival urinary and sexual function can be significantly affected and can be long lasting. HDR-BT, a type of focal radiation therapy also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving HDR-BT may be effective in providing local control while reducing side effects in patients with prostate cancer.
Who can participate
Age range
40 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histologically confirmed diagnosis of prostate adenocarcinoma within 90 days prior to registration via systematic biopsy
* Multiparametric MRI (mp-MRI) confirmed lesion(s)
* No distant or locally advanced disease on standard staging exams as indicated
* Bone scan and abdominopelvic computed tomography (CT)/MRI OR
* PSMA PET
* Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status 0/1 within 60 days prior to enrollment
* Age ≥ 40
Exclusion Criteria:
* Radiographic nodal or distant metastatic disease
* Lesion(s) comprising \> 40% of total prostate volume
* Prior radiotherapy to the pelvis
* Gleason score \> 6 disease outside intended gross target volume (GTV)/target region(s)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of grade 2 or greater genitourinary adverse events (AEs)
Timeframe: Up to 6 years
2
Incidence of grade 2 or greater gastrointestinal AEs